| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/30/2004 | EP1432697A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432696A1 Chroman derivatives as 5-hydroxytryptamine-6 ligands |
| 06/30/2004 | EP1432693A2 Mch receptor antagonists |
| 06/30/2004 | EP1432691A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
| 06/30/2004 | EP1432690A2 Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence |
| 06/30/2004 | EP1432689A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders |
| 06/30/2004 | EP1432687A2 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 06/30/2004 | EP1432686A1 Tetrahydroisochinolines, their production and the use thereof as analgesics |
| 06/30/2004 | EP1432684A2 Pyridinic sulfonamide derivatives, method of production and use thereof |
| 06/30/2004 | EP1432683A1 Novel crystalline polymorphic forms of lercanidipine hydrochloride and processes for their preparation |
| 06/30/2004 | EP1432681A1 Pseudopolymorphic forms of carvedilol |
| 06/30/2004 | EP1432680A1 Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones |
| 06/30/2004 | EP1432679A1 Preparation and use of pyrrole derivatives for treating obesity |
| 06/30/2004 | EP1432678A1 Hiv protease inhibitors |
| 06/30/2004 | EP1432677A1 Novel urea oligomers, the preparation method thereof and pharmaceutical compositions containing same |
| 06/30/2004 | EP1432669A1 4-(c2-6 alkoxy)-substituted chalcones as therapeutic agents |
| 06/30/2004 | EP1432459A1 Inhibition of exoprotein production using aromatic compositions |
| 06/30/2004 | EP1432458A1 Inhibition of exoproteins using isoprenoids |
| 06/30/2004 | EP1432453A1 Stilbene derivatives and their use for binding and imaging amyloid plaques |
| 06/30/2004 | EP1432452A2 Inhibition of stat-1 |
| 06/30/2004 | EP1432441A2 Use of hmgb1 for the activation of dendritic cells |
| 06/30/2004 | EP1432440A2 Adjuvants for nucleic acid vaccines |
| 06/30/2004 | EP1432438A2 Use of rank antagonists to treat cancer |
| 06/30/2004 | EP1432436A2 Nutrient therapy for immuno-compromised patients |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432425A1 A method of reducing the "in vivo" cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) |
| 06/30/2004 | EP1432424A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions |
| 06/30/2004 | EP1432423A2 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 06/30/2004 | EP1432422A2 Use of c-kit inhibitors for the treatment of myeloma |
| 06/30/2004 | EP1432421A1 Quinoline derivatives as neuropeptide y antagonists |
| 06/30/2004 | EP1432420A2 Benzimidazolidinone derivatives as muscarinic agents |
| 06/30/2004 | EP1432419A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers |
| 06/30/2004 | EP1432418A1 Treatment of hepatitis b virus infection with human monoclonal antibodies |
| 06/30/2004 | EP1432417A2 Substituted benzimidazole compounds and their use for the treatment of cancer |
| 06/30/2004 | EP1432416A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/30/2004 | EP1432415A1 Substituted 2,5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases |
| 06/30/2004 | EP1432414A1 Use of tazarotene for preparing a nail varnish for treating and/or preventing psoriasis and nail varnish containing same |
| 06/30/2004 | EP1432413A2 3,4-methylenedioxy-substituted chalcones as therapeutic agents |
| 06/30/2004 | EP1432412A2 Antioxidant combination composition and use thereof |
| 06/30/2004 | EP1432411A1 Timed, sustained release multi-particulate dosage forms of propranolol |
| 06/30/2004 | EP1432410A2 Process for the preparation of fast dissolving effervescent dosage form |
| 06/30/2004 | EP1432408A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 06/30/2004 | EP1432405A1 Ibuprofen salt emulsifiers and cream formulations containing same |
| 06/30/2004 | EP1432404A1 Edible composition and dosage form comprising an edible shell |
| 06/30/2004 | EP1432403A2 Liposome loading with metal ions |
| 06/30/2004 | EP1432402A2 Compositions for delivery of drug combinations |
| 06/30/2004 | EP1432399A1 Enhancing epidermal barrier development in skin |
| 06/30/2004 | EP1432379A1 Methods for inhibiting cognitive deterioration in adults with down's syndrome |
| 06/30/2004 | EP1432313A1 N-thio-nicotinamide derivatives and related compounds for use as pesticides |
| 06/30/2004 | EP1432312A1 Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues |
| 06/30/2004 | EP1432310A2 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
| 06/30/2004 | EP1385509A4 Method of treatment |
| 06/30/2004 | EP1315730B1 1-(alkyl), 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo(1,2-a)pyrimidin-5(1h)-one derivatives |
| 06/30/2004 | EP1313379B1 Alpha-(1,4)linked glucose polymers containing oral compositions to alleviate or prevent tooth damage |
| 06/30/2004 | EP1282625B1 Benzoxazines for use in the treatment of parkinson's disease |
| 06/30/2004 | EP1264548A4 Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy |
| 06/30/2004 | EP1237857B1 New phenalkyloxy-phenyl derivatives |
| 06/30/2004 | EP1237543A4 Effervescent histamine h2 antagonist composition |
| 06/30/2004 | EP1237524A4 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 06/30/2004 | EP1227817B1 Ciclesonide-containing aqueous pharmaceutical composition |
| 06/30/2004 | EP1214313B1 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same |
| 06/30/2004 | EP1206281B1 Formulation containing moxifloxacin and sodium chloride |
| 06/30/2004 | EP1178982B1 Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 06/30/2004 | EP1149072B1 Sulfonamide hydroxamates |
| 06/30/2004 | EP1128726B1 Teat disinfectant |
| 06/30/2004 | EP1121146B1 Utilization of proteolytic enzymes to influence hyperactive t cells |
| 06/30/2004 | EP1113802B1 Antiviral combinations of lamivudine and adefovir |
| 06/30/2004 | EP1112366B1 Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses |
| 06/30/2004 | EP1082299B1 C11 oxymyl and hydroxylamino prostaglandins useful as medicaments |
| 06/30/2004 | EP1080081B1 Benzofuroxan derivatives and their use in treating angina pectoris |
| 06/30/2004 | EP1070056B1 Phthalazinone pde iii/iv inhibitors |
| 06/30/2004 | EP1070049B1 Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| 06/30/2004 | EP1054688B1 Method for selecting tumours expressing hla-g, sensitive to anticancer treatment and uses |
| 06/30/2004 | EP1045693B1 Aminophenoxyacetic acid derivatives as neuroprotectants |
| 06/30/2004 | EP1037880B1 Retinoic acid mimetic anilides |
| 06/30/2004 | EP1019408B1 1,2,3,4-TETRAHYDRO-BENZOFURO[3,2-c]PYRIDINE DERIVATIVES |
| 06/30/2004 | EP1009743B1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation |
| 06/30/2004 | EP1000053B1 Macrocyclic lactones, compositions, and methods of use |
| 06/30/2004 | EP0977560B1 IBUPROFEN THIOESTERS AS INHIBITORS OF Nf-kappaB-DEPENDENT PAIN AND INFLAMMATION MEDIATOR FORMATION |
| 06/30/2004 | EP0975640B1 Vinca alkaloid antimitotic halogenated derivatives |
| 06/30/2004 | EP0975596B1 Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors |
| 06/30/2004 | EP0971908B1 Il-8 receptor antagonists |
| 06/30/2004 | EP0958289B1 Amino acid ester containing azole antifungals |
| 06/30/2004 | EP0945436B1 Cytotrienins, process for preparing the same, and antitumor agent |
| 06/30/2004 | EP0939630B1 Use of benzopyranols to treat neurological disorders |
| 06/30/2004 | EP0876817B1 Remedy for keratoconjunctival diseases |
| 06/30/2004 | EP0862628B1 Receptor and nucleic acid molecule encoding said receptor |
| 06/30/2004 | EP0851876B1 Antisecretory factor peptides regulating pathological permeability changes |
| 06/30/2004 | EP0841897B2 Physically active antimicrobial gel for cosmetic products |
| 06/30/2004 | EP0832875B1 Highly water-soluble metalloproteinase inhibitor |
| 06/30/2004 | CN1509462A Use of NF-kappa-B inhibitors in treatment of dry disorders |
| 06/30/2004 | CN1509337A New polynucleotides and polypeptides of IFN alpha-17 gene |
| 06/30/2004 | CN1509335A Topoisomerase I selective cytotoxic sugar derivatives of indolopyrrolocarbazoles |
| 06/30/2004 | CN1509292A Combination apparoach to treatment of cancer using C-MYC antisense oligomer |
| 06/30/2004 | CN1509291A Oxazolo-and-furopyrimidines and their use in medicaments against tumors |
| 06/30/2004 | CN1509289A Imidazo[1,5,-A] pyrimido[5,4-d]benzazepine derivatives as GABAA receptor medulators |
| 06/30/2004 | CN1509288A The citrate salt of 5,8,14-triazatetracyclo (10.3.1.0.2,11.0.4,9)-hexadeca-2.(11),3,5,7,9-pentaene |
| 06/30/2004 | CN1509287A Aryl-8-azabicyclo[3,2,1]octanes for treating depression |
| 06/30/2004 | CN1509286A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509283A Novel pyridyl cyanoguandine compounds |